2020 'Invest in the Greater Bay Area · Co-create the Future' Precision Financing Matchmaking Event for SMEs in the GBA
The sudden outbreak of the COVID-19 pandemic,
Imposing an unprecedented and massive shock on healthcare innovation and entrepreneurship ventures.
To alleviate enterprises' difficulties in capital turnover and their urgent need for financing,
Connecting Investment Institutions with Healthcare Startup Projects
“Meeting-free” yet successfully “joining hands,”
Under the guidance of the Guangzhou Development District Financial Affairs Bureau,
Jointly initiated by Guangzhou Tengfei Park and Guan Hao Life Health Science and Technology Park
2020“Invest in the Greater Bay Area, Create and Share the Future”
Precision Financing Matchmaking Conference for SMEs in the Guangdong-Hong Kong-Macao Greater Bay Area。
Organizing Unit
Guiding Organizations
Guangzhou Development District Financial Affairs Bureau
Organizer
Guanhao Life Health Technology Park Co., Ltd.
Guangzhou Knowledge City Tefei Science and Technology Park Development Co., Ltd.
Co-organizer
Guangdong Haosai Technology Enterprise Incubator Co., Ltd.
Supporting Organizations
VCBeat
Event Details
I. Event Schedule
Thursday, April 23, 2020, 10:00–12:00
II. Event Highlights
1. Joint Efforts to Facilitate Precision Financing
Through the joint invitation of the Guangzhou Development District Financial Bureau, Guan Hao Technology Park, and Tengfei Park, senior investors from investment institutions were invited for on-site exchanges, one-on-one matchmaking, professional analysis, and in-depth discussions of projects, effectively addressing corporate financing challenges.
2. Coverage by Professional Media Outlets
In-depth interviews and reports by professional media, collaborative efforts to jointly promote dissemination, leveraging industry and expert influence to increase project exposure, and collectively facilitating the translation of achievements into practical applications.
3. Join the Bay Area Biomedical Community
Seamlessly connect with resources, network with healthcare investors and entrepreneurs, gain insights into industry trends, expand your professional network, negotiate collaborations, and build a robust circle of industry contacts.
III. Activity Format
Live Video Streaming
IV. Event Agenda
Time | Event |
9:50—10:00 | Publish Online Livestream Link |
10:00—10:05 | Opening Remarks |
10:05—10:20 | Guest Leader's Address |
10:20—10:30 | Project Pitch Session 1 |
10:30—10:40 | Project Pitch Session II |
10:40—10:50 | Project Pitch III |
10:50—11:00 | Free Exchange |
11:00—12:00 | One-on-One In-Person Consultation |
V. Roadshow Projects
1
Guangzhou Xinrui Medical Technology Co., Ltd.
ItemIntroductionShao：
The companyThe team has 15 years of China-U.S.PathologyMarket, 20 years of artificial intelligence andAccelerated ClothingServer development experience. Possesses hardware-based AI pathology solutions, slide digitization scanners, and modular acceleration servers specifically designed for AI algorithms that process large-scale pathology data.
Project Highlights:
(1) Joint development and clinical trials conducted in collaboration with multiple renowned Grade-A tertiary hospitals;
(2) The team has 15 years of experience in the China-US pathology market and 20 years of experience in artificial intelligence and accelerated server development;
（3）Established in the Development Zone in April 2019. It is a Guangzhou Entrepreneurial Leading Team Project, receiving RMB 24.8 million in talent and project subsidies from the Guangzhou Municipal Government and the Development Zone. The company ranked second in the startup category of the Guangdong Division of the Innovation and Entrepreneurship Competition and was recognized as an Outstanding Enterprise in the National Competition.
Financing Amount:10 million
2
Guangzhou Hua'ao Biotechnology Co., Ltd.
Project Introduction：
Positioned as a leader in the POCT sector for women’s and children’s health, the company has already established a strong reputation. Its product portfolio comprises test strip-based and reagent-based production lines, with its standard products in both categories ranking first nationwide. It has currently establishedMilkGel MethodOur technology platforms include immunochromatography, quantitative fluorescence detection, and chemiluminescence. Our product portfolio spans multiple fields, including infectious diseases, inflammation, cardiovascular diseases, oncology, and metabolic disorders.
Project Highlights：
The company has approximately 18 clean production workshops.00 square meterssquare meters, divided into test strip production lines and reagent production lines. We have established technical platforms for latex-based immunochromatography, quantitative fluorescence detection, and chemiluminescence. Our product portfolio covers infectious diseases, inflammation, cardiovascular diseases, oncology, and metabolic disorders. We boast a professional R&D team composed of experts in medicine, pharmacy, and laboratory science, currently comprising 15 registered researchers. We are continuously introducing new projects, striving to build an industry focused on novel medical diagnostic technologies, aligning with national policies, committing to the cause of human health, and contributing to the advancement of medical science in China.
Financing Amount:30 million
Kangruide (Guangzhou) Health Technology Co., Ltd.
Project Introduction：
Focus on Women's Reproductive Health,It reduces the incidence of female diseases such as cervical cancer and breast cancer, has obtained multiple patents, and its treatment protocol design and technical operational procedures are industry-leading.
Project Highlights：
(1) Preparation and application of a soybean protein-based polymeric hydrogel with good biocompatibility and swelling properties. Patent No.: ZL201510366291.0, Certificate No.: 2659614;
(2) Preparation of a soy protein-based dual-responsive macroporous hydrogel and its application as a drug carrier. Patent No.: ZL201510364897.0, Certificate No.: 2690930;
(3) A method for extracting pear polyphenols. Patent No.: ZL201210530633.4; Certificate No.: 1780650;
(4) The HPV gel was tested by the Academy of Military Medical Sciences of the Chinese People's Liberation Army. The issued test report is an official document released by the institute to external parties, which indicates that the product achieves a bacteriostatic rate of >99.9% against Staphylococcus aureus, >99.9% against Escherichia coli, and >99.9% against Candida albicans.
Financing Amount:5 million
VI. Event Registration
Scan the QR code,
Join the event WeChat group!
Contact
Guanhao Technology Park, Ms. Wu, 15800038413（(WeChat ID is the same)